Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sofosbuvir plus Daclatasvir in Chinese treatment-experienced HCV G1b
NCT02473211Phase 3Completed
- Sponsor
- Humanity & Health Research Centre
- Start
- Jan 2015
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of sofosbuvir and daclatasvir in hepatitis C (HCV), sponsored by Humanity & Health Research Centre. Primary endpoint: Sustained Virologic Response 12 weeks after end of treatment. Started Jan 2015; status: completed.
02
Drugs
sofosbuvirdaclatasvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT02473211.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02473211.